Table. 1.

Table. 1.

Key characteristics of the 3 haplo-HSCT platoforms

Ex vivo T cell depleted HSCT

Potential for very low incidence of acute and chronic GVHD

No pharmacologic immunosuppression after HSCT

Higher risk of delayed immune reconstitution and infectious complications, such as HHV-6 infection

Requirement of equipment and expertise necessary for ex vivo T cell depletion

Post-transplantation cyclophosphamide

Relatively simple regimen which allows for haplo-HSCT in resource limited settings

Risk of lower rate of engraftment if undertaken within the context of reduced intensity conditioning

Possibly a limited role in patients with high susceptibility to alkylating agent toxicity, such as Fanconi anemia patients

Follow-up is necessary to determine long-term complications of high dose Cy, such as cardiac dysfunction

GIAC protocol

Incorporates myeloablative conditioning which may allow for lower incidence of relapse

Higher incidence of acute and chronic GVHD

Lengthy period of pharmacologic immunosuppression with multiple agents, which may predispose to increased nonrelapse mortality

Clin Pediatr Hematol Oncol 2021;28:67-74
© 2021 Clin Pediatr Hematol Oncol